GlaxoSmithKline Partner Pronova BioPharma Settles Drug Case with Apotex Inc.; Apotex to Sell Generic Lovaza in U.S. from Q1 2015

March 30, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, March 30 (Reuters) - Norway's Pronova BioPharma (PRON.OL), which supplies the omega-3 heart medicine Lovaza to GlaxoSmithKline (GSK.L), settled a U.S. patent row with generics company Apotex, sending Pronova shares sharply higher.

Twitter
LinkedIn
Facebook
Email
Print

Legal

GSK